Product name
AptaC - inhibition of thrombin-induced platelet aggregation and highly specific detection of activated protein C from University BonnSummary
Aptamers and fusion aptamers binding haemostatic molecules for diagnostic and therapeutic useOrganization name
ProvendisProfile
Aptamers as diagostic tools
The inventions provide aptamers as diagnostic tools for detection of APC in biological samples also in the presence of abundant inactive protein C with high selective specificity. This allows establishment of routine diagnostics for APC to analyse disturbances in haemostasis, e.g. in sepsis or in haemophilia A. Further the inventions provide therapeutic aptamers binding to APC for the control of bleeding events, e.g. in haemophilia A or Willebrand syndrome.
Inhibition of thrombin-induced platelet aggregation
In another embodiment of the inventions, linkage of aptamers HD1 and HD22 by a poly-dA-linker generates a fusion aptamer, named HD1-22, that binds with higher affinity to thrombin than the original aptamers.
The determined effect of HD1-22 on thrombin-induced platelet aggregation using washed human platelets showed superior inhibitory activity as an equimolar mixture of both precursor aptamers. Under the conditions tested, HD1-22 was found two-fold more effective as bivalirudin and »5-fold more active as argatroban.
Photo-activated aptamers
Additionally the inventions comprise aptamers binding to haemostatic target molecules, such aptamers being activated to covalently bind to the target molecules by application of light. Such photo-activated aptamers could be used for example for the control of bleeding and occlusion in surgical procedures.
Benefits
- Highly selective detection of APC for routine diagnostics;
- Modulation of APC for prophylaxis and treatment of bleeding disorders;
- Fusion Aptamers with higher affinity and superior inhibitory activity on thrombin-induced platelet aggregation;
- Photo-activated aptamers for modulation of haemostatic targets;
- Stability and low toxicity of aptamers;
- Possibility of rapidly neutralisation by addition of antidote oligonucleotides;
- Low production costs.
Contact
Dr. Andreas Wagener
Tel: +49 208 94 105 38
aw(at)provendis.info
About PROvendis GmbH
PROvendis offers companies certified and patented innovations from 24 North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.
Description File
1403_1618_1626_TA-Aae2d5008_01.pdf
print this page
